Drug Type Synthetic peptide |
Synonyms Cyclin A/B inhibitors(Circle) |
Target |
Mechanism CCNB1 inhibitors(cyclin B1 inhibitors), cyclin-A inhibitors(cyclin A2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Start Date14 Aug 2024 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 14 Aug 2024 | |
Lung Cancer | Phase 1 | US | 14 Aug 2024 | |
Metastatic Solid Tumor | Phase 1 | US | 14 Aug 2024 | |
Neuroendocrine Carcinoma | Phase 1 | US | 14 Aug 2024 | |
Triple Negative Breast Cancer | Phase 1 | US | 14 Aug 2024 | |
ER-low Breast cancer | IND Application | US | 01 Jul 2024 | |
Hormone receptor positive breast cancer | IND Application | US | 01 Jul 2024 | |
Small Cell Lung Cancer | IND Application | US | 01 Jul 2024 | |
Non-Small Cell Lung Cancer | Preclinical | US | 19 Jul 2023 | |
Pancreatic Cancer | Preclinical | US | 19 Jul 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |